Chordate Medical Holding AB (publ) (CMH.ST)
SEK 12.6
(-1.18%)
SEK 12.6
(-1.18%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | -100.0% |
| 2018 | 1.5 Million SEK | -73.68% |
| 2017 | 5.7 Million SEK | 111.11% |
| 2016 | 2.7 Million SEK | -64.47% |
| 2015 | 7.6 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 FY | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 FY | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q4 | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q1 | 1.5 Million SEK | 0.0% |
| 2019 FY | - SEK | -100.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 1.5 Million SEK | -73.68% |
| 2018 Q4 | 1.5 Million SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | -100.0% |
| 2017 FY | 5.7 Million SEK | 111.11% |
| 2017 Q3 | 2.7 Million SEK | 0.0% |
| 2017 Q1 | 2.7 Million SEK | 0.0% |
| 2017 Q4 | 5.7 Million SEK | 111.11% |
| 2016 FY | 2.7 Million SEK | -64.47% |
| 2016 Q4 | 2.7 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 7.6 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | NaN% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 100.0% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 100.0% |
| Arcoma AB | 1.92 Million SEK | 100.0% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 100.0% |
| BICO Group AB (publ) | 1.75 Billion SEK | 100.0% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 100.0% |
| CellaVision AB (publ) | 28.66 Million SEK | 100.0% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | 100.0% |
| C-Rad AB (publ) | 1.75 Million SEK | 100.0% |
| Duearity AB (publ) | 2.94 Million SEK | 100.0% |
| Dignitana AB (publ) | 6.07 Million SEK | 100.0% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 100.0% |
| Getinge AB (publ) | 3.9 Billion SEK | 100.0% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 100.0% |
| Iconovo AB (publ) | 4.9 Million SEK | 100.0% |
| Integrum AB (publ) | 4.84 Million SEK | 100.0% |
| Luxbright AB (publ) | 206.02 Thousand SEK | 100.0% |
| Mentice AB (publ) | 2.14 Million SEK | 100.0% |
| OssDsign AB (publ) | 214 Thousand SEK | 100.0% |
| Paxman AB (publ) | 2.53 Million SEK | 100.0% |
| Promimic AB (publ) | - SEK | NaN% |
| Qlife Holding AB (publ) | 3 Million SEK | 100.0% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 100.0% |
| ScandiDos AB (publ) | - SEK | NaN% |
| Sectra AB (publ) | 19.2 Million SEK | 100.0% |
| Sedana Medical AB (publ) | 1.01 Million SEK | 100.0% |
| Senzime AB (publ) | 8.57 Million SEK | 100.0% |
| SpectraCure AB (publ) | 4.39 Million SEK | 100.0% |
| Stille AB | 38.06 Million SEK | 100.0% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 100.0% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 100.0% |